20.11.2025 13:27:16 CET | Thor Medical ASA | Additional regulated information required to be disclosed under the laws of a member state

Oslo, Norway, 20 November 2025 – Reference is made to the stock exchange announcement made by Thor Medical ASA on 11 November 2025 regarding issuance of 1,090,974 new shares pursuant to the Company's restricted share units program. The share issue has now been registered in the Norwegian Register of Business Enterprises and the Company's new share capital is NOK 70,815,378.80 dividend into 354,076,894 shares, each with a nominal value of NOK 0.20. Each share represents one vote in the Company's general meeting.

For further information please contact:

Brede Ellingsæter, CFO and COO,

Tel: +47 472 38 440,

Email: brede.ellingseter@thormedical.no

‍

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of alpha particle emitters produced from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

‍

This information is subject to the disclosure requirements pursuant to section 5-12 of the Securities Trading Act.

‍

Attachments

• Download announcement as PDF.pdf

‍